Diffusion Pharmaceuticals Inc (DFFN)

[staccani]

Please in the attched link ph2 GBM study detailed results. 40% of the 14 inoperable GBM patients surviving 2 years. 11 of the 59 patients achieving CR. Simply outstanding. My guess is that these results may be even improved considering the concomitant and continuous administration of TSC during the whole trial, cuopled with escalating doseage, but I would not mind if they are simply confirmed. What is more important is the proof of concept applicable to basically all cancers. This is all very exciting , we should hear about the results of the ph3 8 patients initial cohort shortly (this initial phase is expected to be completed in Q2 2019)

https://thejns.org/view/journals/j-neurosurg/126/2/article-p460.xml